Avoro Capital Advisors LLC Nuvalent, Inc. Transaction History

Avoro Capital Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$42.42 - $80.28 $26.9 Million - $50.9 Million	-633,579 Reduced 77.98%	178,921 $13.2 Million
Q3 2023 Nov 14, 2023	SELL	$39.12 - $49.85 $30.8 Million - $39.3 Million	-787,500 Reduced 49.22%	812,500 $37.4 Million
Q2 2023 Aug 14, 2023	SELL	$23.58 - $44.68 $6.81 Million - $12.9 Million	-288,888 Reduced 15.29%	1,600,000 $67.5 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $8.47 Million - $11.2 Million	333,333 Added 21.43%	1,888,888 $49.3 Million
Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $9.34 Million - $18.4 Million	506,084 Added 48.22%	1,555,555 $46.3 Million
Q1 2022 May 16, 2022	SELL	$11.65 - $19.57 $619,780 - $1.04 Million	-53,200 Reduced 4.82%	1,049,471 $14.6 Million
Q4 2021 Feb 14, 2022	SELL	$18.01 - $30.1 $2.79 Million - $4.67 Million	-155,000 Reduced 12.32%	1,102,671 $18.4 Million
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $23 Million - $48.2 Million	1,257,671 New	1,257,671 $22.3 Million

209

59.5M

450K

619K

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.62B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.